Risk of mortality in patients with psoriatic arthritis, rheumatoid arthritis and psoriasis: a longitudinal cohort study.
dc.contributor.author | Ogdie, Alexis | |
dc.contributor.author | Haynes, Kevin | |
dc.contributor.author | Troxel, Andrea B | |
dc.contributor.author | Love, Thorvardur Jon | |
dc.contributor.author | Hennessy, Sean | |
dc.contributor.author | Choi, Hyon | |
dc.contributor.author | Gelfand, Joel M | |
dc.date.accessioned | 2014-08-29T13:56:18Z | |
dc.date.available | 2014-08-29T13:56:18Z | |
dc.date.issued | 2014-01 | |
dc.date.submitted | 2014 | |
dc.identifier.citation | Ann. Rheum. Dis. 2014, 73 (1):149-53 | en |
dc.identifier.issn | 1468-2060 | |
dc.identifier.pmid | 23264338 | |
dc.identifier.doi | 10.1136/annrheumdis-2012-202424 | |
dc.identifier.uri | http://hdl.handle.net/2336/325566 | |
dc.description.abstract | There are conflicting reports in the literature of the mortality risk among patients with psoriatic arthritis (PsA). The objective of this study was to examine the risk of mortality in patients with PsA compared with matched controls, patients with psoriasis and those with rheumatoid arthritis (RA). | |
dc.description.abstract | A longitudinal cohort study was performed in a large UK medical record database, The Health Improvement Network, among patients with PsA, rheumatoid arthritis (RA) or psoriasis with data from 1994 to 2010. Unexposed controls were matched on practice and start date within the practice for each patient with PsA. Cox proportional hazards models were used to calculate the relative hazards for death. | |
dc.description.abstract | Patients with PsA (N=8706), RA (N=41 752), psoriasis (N=138 424) and unexposed controls (N=82 258) were identified; 1 442 357 person-years were observed during which 21 825 deaths occurred. Compared with population controls, patients with PsA did not have an increased risk of mortality after adjusting for age and sex (disease-modifying antirheumatic drug (DMARD) users: HR 0.94, 95% CI 0.80 to 1.10; DMARD non-users: HR 1.06, 95% CI 0.94 to 1.19) whereas patients with RA had increased mortality (DMARD users: HR 1.59, 95% CI 1.52 to 1.66; DMARD non-users: HR 1.54, 95% CI 1.47 to 1.60). Patients with psoriasis who had not been prescribed a DMARD had a small increased risk of mortality (HR 1.08, 95% CI 1.04 to 1.12) while those who had been prescribed a DMARD, indicating severe psoriasis, were at increased risk (HR 1.75, 95% CI 1.56 to 1.95). | |
dc.description.abstract | Patients with RA and psoriasis have increased mortality compared with the general population but patients with PsA do not have a significantly increased risk of mortality. | |
dc.description.sponsorship | American College of Rheumatology Clinical and Translational Science Award at the University of Pennsylvania from the National Center for Research Resources/8UL1TR000003 NIH/T32 GM075766-05 American College of Rheumatology Research and Education Foundation Icelandic Research Fund /120433021/R01AG025152 R01HL111293 | en |
dc.language.iso | en | en |
dc.publisher | Bmj Publishing Group | en |
dc.relation.url | http://dx.doi.org/10.1136/annrheumdis-2012-202424 | en |
dc.relation.url | http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3883139/ | en |
dc.relation.url | http://ard.bmj.com/content/73/1/149.full.pdf+html | en |
dc.rights | Archived with thanks to Annals of the rheumatic diseases | en |
dc.subject | Sóríasis | en |
dc.subject | Gigtarsjúkdómar | en |
dc.subject | Iktsýki | en |
dc.subject | Áhættuþættir | en |
dc.subject | Tíðni | en |
dc.subject.mesh | Adolescent | en |
dc.subject.mesh | Adult | en |
dc.subject.mesh | Aged | en |
dc.subject.mesh | Aged, 80 and over | en |
dc.subject.mesh | Arthritis, Psoriatic | en |
dc.subject.mesh | Arthritis, Rheumatoid | en |
dc.subject.mesh | Cohort Studies | en |
dc.subject.mesh | Female | en |
dc.subject.mesh | Humans | en |
dc.subject.mesh | Incidence | en |
dc.subject.mesh | Longitudinal Studies | en |
dc.subject.mesh | Male | en |
dc.subject.mesh | Middle Aged | en |
dc.subject.mesh | Proportional Hazards Models | en |
dc.subject.mesh | Psoriasis | en |
dc.subject.mesh | Risk Factors | en |
dc.subject.mesh | Young Adult | en |
dc.title | Risk of mortality in patients with psoriatic arthritis, rheumatoid arthritis and psoriasis: a longitudinal cohort study. | en |
dc.type | Article | en |
dc.contributor.department | Univ Penn, Ctr Clin Epidemiol & Biostat, Ctr Pharmacoepidemiol Res & Training, Div Rheumatol,Perelman Sch Med, Philadelphia, PA 19104 USA, Univ Penn, Ctr Clin Epidemiol & Biostat, Ctr Pharmacoepidemiol Res & Training, Dept Biostat & Epidemiol,Perelman Sch Med, Philadelphia, PA 19104 USA, Landspitali Univ Hosp, Div Rheumatol, Reykjavik, Iceland, Boston Univ, Sch Med, Rheumatol Sect, Boston, MA 02118 USA, Boston Univ, Sch Med, Clin Epidemiol Unit, Boston, MA 02118 USA, Univ Penn, Ctr Clin Epidemiol & Biostat, Ctr Pharmacoepidemiol Res & Training, Dept Dermatol,Perelman Sch Med, Philadelphia, PA 19104 USA | en |
dc.identifier.journal | Annals of the rheumatic diseases | en |
dc.rights.access | Landspitali Access - LSH-aðgangur | en |
html.description.abstract | There are conflicting reports in the literature of the mortality risk among patients with psoriatic arthritis (PsA). The objective of this study was to examine the risk of mortality in patients with PsA compared with matched controls, patients with psoriasis and those with rheumatoid arthritis (RA). | |
html.description.abstract | A longitudinal cohort study was performed in a large UK medical record database, The Health Improvement Network, among patients with PsA, rheumatoid arthritis (RA) or psoriasis with data from 1994 to 2010. Unexposed controls were matched on practice and start date within the practice for each patient with PsA. Cox proportional hazards models were used to calculate the relative hazards for death. | |
html.description.abstract | Patients with PsA (N=8706), RA (N=41 752), psoriasis (N=138 424) and unexposed controls (N=82 258) were identified; 1 442 357 person-years were observed during which 21 825 deaths occurred. Compared with population controls, patients with PsA did not have an increased risk of mortality after adjusting for age and sex (disease-modifying antirheumatic drug (DMARD) users: HR 0.94, 95% CI 0.80 to 1.10; DMARD non-users: HR 1.06, 95% CI 0.94 to 1.19) whereas patients with RA had increased mortality (DMARD users: HR 1.59, 95% CI 1.52 to 1.66; DMARD non-users: HR 1.54, 95% CI 1.47 to 1.60). Patients with psoriasis who had not been prescribed a DMARD had a small increased risk of mortality (HR 1.08, 95% CI 1.04 to 1.12) while those who had been prescribed a DMARD, indicating severe psoriasis, were at increased risk (HR 1.75, 95% CI 1.56 to 1.95). | |
html.description.abstract | Patients with RA and psoriasis have increased mortality compared with the general population but patients with PsA do not have a significantly increased risk of mortality. |